John A. Olson
Washington University in St. Louis · 147 works · 12,895 citations · h-index 38
Top works
- Predicting the clinical status of human breast cancer by using gene expression profiles
- Oncogenic pathway signatures in human cancers as a guide to targeted therapies
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- Whole-genome analysis informs breast cancer response to aromatase inhibition
- Parathyroid Autotransplantation During Thyroidectomy
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
- Impact of Immediate Versus Delayed Axillary Node Dissection on Surgical Outcomes in Breast Cancer Patients With Positive Sentinel Nodes: Results From American College of Surgeons Oncology Group Trials Z0010 and Z0011
- Magnetic Resonance Imaging Facilitates Breast Conservation for Occult Breast Cancer
- Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
- PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer
- Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
- Thyroid Cancer Clinical Practice Guidelines in Oncology
- Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy
- Sentinel Lymphadenectomy Accurately Predicts Nodal Status in T2 Breast Cancer
- An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer
- Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome
- Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx